Strata Critical Medical (SRTA) Cash & Current Investments (2019 - 2026)

Strata Critical Medical (SRTA) has reported Cash & Current Investments for 8 consecutive years, with $330000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 99.62% year-over-year to $330000.0; the TTM figure through Mar 2026 stood at $330000.0 (down 99.62% YoY), while the FY2025 annual figure was $61.2 million, down 44.35% from the prior year.
• Cash & Current Investments retreated to $330000.0 in Q1 2026 per SRTA's latest filing, from $61.2 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $269.1 million in Q1 2022 and bottomed at $330000.0 in Q1 2026.
• Historically, Cash & Current Investments has averaged $131.9 million across 5 years, with a median of $137.9 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Current Investments soared 64732.77% — and 2026, when it sank 99.62%.
• Strata Critical Medical's Cash & Current Investments stood at $153.8 million in 2022, then climbed by 8.0% to $166.1 million in 2023, then sank by 33.77% to $110.0 million in 2024, then plunged by 44.35% to $61.2 million in 2025, then sank by 99.46% to $330000.0 in 2026.
• Business Quant data shows SRTA's Cash & Current Investments at $330000.0 in Q1 2026, $61.2 million in Q4 2025, and $53.4 million in Q3 2025.